'Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments'

Drug Effects ◽

Cardiovascular Outcome ◽

Outcome Assessments

Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments

European Heart Journal ◽

10.1093/eurheartj/ehr019 ◽

2011 ◽

Vol 32 (15) ◽

pp. 1832-1834 ◽

Cited By ~ 17

Author(s):

M. O. Gore ◽

D. K. McGuire

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Drug Effects ◽

Cardiovascular Outcome ◽

Outcome Assessments

Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus

Statistics in Biopharmaceutical Research ◽

10.1080/19466315.2017.1280411 ◽

2017 ◽

Vol 9 (4) ◽

pp. 347-360 ◽

Cited By ~ 2

Author(s):

Olga Marchenko ◽

Qi Jiang ◽

Christy Chuang-Stein ◽

Cyrus Mehta ◽

Mark Levenson ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Outcome ◽

Cardiovascular Outcome Trials

Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

Current Vascular Pharmacology ◽

10.2174/1570161114666160909161537 ◽

2016 ◽

Vol 14 (5) ◽

pp. 469-473 ◽

Cited By ~ 6

Author(s):

Vasilios G. Athyros ◽

Niki Katsiki ◽

Nikolaos Tentolouris

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Macrovascular Complications ◽

Cardiovascular Outcome ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2019.04.003 ◽

2019 ◽

Vol 43 (7) ◽

pp. 538-545.e2 ◽

Cited By ~ 4

Author(s):

Osamah M. Alfayez ◽

Abdulaali R. Almutairi ◽

Ali Aldosari ◽

Majed S. Al Yami

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Cardiovascular Safety ◽

Cardiovascular Outcome Trials

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus

Clinical Therapeutics ◽

10.1016/j.clinthera.2016.04.037 ◽

2016 ◽

Vol 38 (6) ◽

pp. 1288-1298 ◽

Cited By ~ 21

Author(s):

Guntram Schernthaner ◽

Marie Helene Schernthaner-Reiter ◽

Gerit-Holger Schernthaner

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Treatment Strategies ◽

Cardiovascular Outcome ◽

Glucose Lowering ◽

Future Treatment

Drugs for type 2 diabetes mellitus: The imperative for cardiovascular outcome assessment

Diabetes and Vascular Disease Research ◽

10.1177/1479164112441527 ◽

2012 ◽

Vol 9 (2) ◽

pp. 85-88 ◽

Cited By ~ 4

Author(s):

M Odette Gore ◽

Darren K McGuire

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Outcome Assessment ◽

Cardiovascular Outcome

CARDIOVASCULAR BENEFIT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RECENT CARDIOVASCULAR OUTCOME TRIALS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(19)30847-2 ◽

2019 ◽

Vol 73 (9) ◽

pp. 239

Author(s):

David Aguilar ◽

Efstratios Koutroumpakis ◽

Heinrich Taegtmeyer

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Cardiovascular Benefit

The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication

Journal of Korean Diabetes ◽

10.4093/jkd.2016.17.4.225 ◽

2016 ◽

Vol 17 (4) ◽

pp. 225

Author(s):

Hyuk-Sang Kwon

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Clinical Impact ◽

Cardiovascular Outcome ◽

Diabetes Medication ◽

Outcome Trial ◽

Outcome Event

Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus

Diabetes Therapy ◽

10.1007/s13300-021-01079-x ◽

2021 ◽

Author(s):

Xiaoling Cai ◽

Linong Ji

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Outcome ◽

Chinese Patients ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Abstract P077: Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Black Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Recent Cardiovascular Outcome Trials

Circulation ◽

10.1161/circ.139.suppl_1.p077 ◽

2019 ◽

Vol 139 (Suppl_1) ◽

Author(s):

Efstratios Koutroumpakis ◽

Heinrich Taegtmeyer ◽

David Aguilar

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Meta Analysis ◽

Cardiovascular Outcome ◽

Black Patients ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1